FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317862796> ?p ?o ?g. }

• W4317862796 endingPage "TPS780" @default.
• W4317862796 startingPage "TPS780" @default.
• W4317862796 abstract "TPS780 Background: Pancreatic adenocarcinoma is an aggressive malignancy with a limited number of therapeutic options. One subset of patients (up to 15%) carries germline and/or somatic mutations in homologous recombination repair genes, most notably BRCA1, BRCA2 and PALB2 amongst others, that confer sensitivity to PARP inhibition. Combinations of PARP inhibitors with anti-PD1 immunotherapy have shown activity in breast and ovarian cancer and have not yet been thoroughly studied in pancreatic cancer. Methods: We designed a single-arm phase 2 investigator-initiated study utilizing the combination of niraparib, a highly selective PARP inhibitor and a dostarlimab, an anti PD1 antibody, in the subset of pancreatic cancer patients with germline or somatic mutations in BRCA1/2, PALB2, BARD1, RAD51C, or RAD51D. Additional inclusion criteria include metastatic pancreatic adenocarcinoma, receipt of a platinum agent in 1st or 2nd line unless contraindicated, and at least 1 but not more than 2 prior lines of systemic therapy not including maintenance. Prior PARP inhibition is allowed, but not immediately prior to enrollment. Exclusion criteria include active unstable autoimmune disease or prior malignancy requiring active treatment within 2 years. Patients are treated with niraparib 200 mg orally once daily on days 1 through 21 of a 21 day cycle. Dostarlimab is administered IV 500 mg every 3 weeks for the 1st 4 cycles and then 1000 mg IV every 6 weeks subsequently. The primary endpoint of the study is the disease control rate at 12 weeks using standard iRECIST criteria. Twenty patients will be enrolled to ensure 19 evaluable. The design has 80% power to detected improvement in disease control rate from 25-50% with significance level of 0.10. Descriptive factors include gene mutated for inclusion, germline/somatic, and platinum refractoriness. Given the size of the study along with genetic heterogeneity there will be no interim analysis. Patients are being enrolled at 3 Mayo clinic sites in Rochester Minnesota, Phoenix Arizona, Jacksonville Florida. To date, 13 patients have been enrolled across all 3 sites. Full accrual is anticipated by early 2023. Correlative studies include genomic characterization of baseline tumors, assessment of immune infiltration of tumor microenvironment, tumor collection for organoid/xenograft, and serial circulating cell-free DNA and immune biomarkers. Trial Identifiers: NCT04493060, Mayo: MC1841. Supported by Glaxo Smith Kline. Clinical trial information: NCT04493060 ." @default.
• W4317862796 created "2023-01-25" @default.
• W4317862796 creator A5002789721 @default.
• W4317862796 creator A5006194799 @default.
• W4317862796 creator A5008026182 @default.
• W4317862796 creator A5016908886 @default.
• W4317862796 creator A5019214686 @default.
• W4317862796 creator A5025469479 @default.
• W4317862796 creator A5033086406 @default.
• W4317862796 creator A5038413156 @default.
• W4317862796 creator A5040564964 @default.
• W4317862796 creator A5043260959 @default.
• W4317862796 creator A5059022515 @default.
• W4317862796 creator A5064791048 @default.
• W4317862796 creator A5069036162 @default.
• W4317862796 creator A5074891676 @default.
• W4317862796 creator A5077416215 @default.
• W4317862796 creator A5082891025 @default.
• W4317862796 date "2023-02-01" @default.
• W4317862796 modified "2023-09-30" @default.
• W4317862796 title "Trial in progress: Phase II study of niraparib and dostarlimab for the treatment of germline or somatic homologous recombination repair mutated metastatic pancreatic cancer." @default.
• W4317862796 doi "https://doi.org/10.1200/jco.2023.41.4_suppl.tps780" @default.
• W4317862796 hasPublicationYear "2023" @default.
• W4317862796 type Work @default.
• W4317862796 citedByCount "1" @default.
• W4317862796 countsByYear W43178627962023 @default.
• W4317862796 crossrefType "journal-article" @default.
• W4317862796 hasAuthorship W4317862796A5002789721 @default.
• W4317862796 hasAuthorship W4317862796A5006194799 @default.
• W4317862796 hasAuthorship W4317862796A5008026182 @default.
• W4317862796 hasAuthorship W4317862796A5016908886 @default.
• W4317862796 hasAuthorship W4317862796A5019214686 @default.
• W4317862796 hasAuthorship W4317862796A5025469479 @default.
• W4317862796 hasAuthorship W4317862796A5033086406 @default.
• W4317862796 hasAuthorship W4317862796A5038413156 @default.
• W4317862796 hasAuthorship W4317862796A5040564964 @default.
• W4317862796 hasAuthorship W4317862796A5043260959 @default.
• W4317862796 hasAuthorship W4317862796A5059022515 @default.
• W4317862796 hasAuthorship W4317862796A5064791048 @default.
• W4317862796 hasAuthorship W4317862796A5069036162 @default.
• W4317862796 hasAuthorship W4317862796A5074891676 @default.
• W4317862796 hasAuthorship W4317862796A5077416215 @default.
• W4317862796 hasAuthorship W4317862796A5082891025 @default.
• W4317862796 hasConcept C104317684 @default.
• W4317862796 hasConcept C109825262 @default.
• W4317862796 hasConcept C121608353 @default.
• W4317862796 hasConcept C126322002 @default.
• W4317862796 hasConcept C13514818 @default.
• W4317862796 hasConcept C143998085 @default.
• W4317862796 hasConcept C182979987 @default.
• W4317862796 hasConcept C2778144015 @default.
• W4317862796 hasConcept C2779138821 @default.
• W4317862796 hasConcept C2779399171 @default.
• W4317862796 hasConcept C2780210213 @default.
• W4317862796 hasConcept C2780427987 @default.
• W4317862796 hasConcept C2781182431 @default.
• W4317862796 hasConcept C501734568 @default.
• W4317862796 hasConcept C502942594 @default.
• W4317862796 hasConcept C54355233 @default.
• W4317862796 hasConcept C71924100 @default.
• W4317862796 hasConcept C82381507 @default.
• W4317862796 hasConcept C86803240 @default.
• W4317862796 hasConceptScore W4317862796C104317684 @default.
• W4317862796 hasConceptScore W4317862796C109825262 @default.
• W4317862796 hasConceptScore W4317862796C121608353 @default.
• W4317862796 hasConceptScore W4317862796C126322002 @default.
• W4317862796 hasConceptScore W4317862796C13514818 @default.
• W4317862796 hasConceptScore W4317862796C143998085 @default.
• W4317862796 hasConceptScore W4317862796C182979987 @default.
• W4317862796 hasConceptScore W4317862796C2778144015 @default.
• W4317862796 hasConceptScore W4317862796C2779138821 @default.
• W4317862796 hasConceptScore W4317862796C2779399171 @default.
• W4317862796 hasConceptScore W4317862796C2780210213 @default.
• W4317862796 hasConceptScore W4317862796C2780427987 @default.
• W4317862796 hasConceptScore W4317862796C2781182431 @default.
• W4317862796 hasConceptScore W4317862796C501734568 @default.
• W4317862796 hasConceptScore W4317862796C502942594 @default.
• W4317862796 hasConceptScore W4317862796C54355233 @default.
• W4317862796 hasConceptScore W4317862796C71924100 @default.
• W4317862796 hasConceptScore W4317862796C82381507 @default.
• W4317862796 hasConceptScore W4317862796C86803240 @default.
• W4317862796 hasIssue "4_suppl" @default.
• W4317862796 hasLocation W43178627961 @default.
• W4317862796 hasOpenAccess W4317862796 @default.
• W4317862796 hasPrimaryLocation W43178627961 @default.
• W4317862796 hasRelatedWork W2138277750 @default.
• W4317862796 hasRelatedWork W2755955412 @default.
• W4317862796 hasRelatedWork W2780324552 @default.
• W4317862796 hasRelatedWork W2914280199 @default.
• W4317862796 hasRelatedWork W2920864397 @default.
• W4317862796 hasRelatedWork W3045464218 @default.
• W4317862796 hasRelatedWork W3089524747 @default.
• W4317862796 hasRelatedWork W3097033023 @default.
• W4317862796 hasRelatedWork W3189666774 @default.
• W4317862796 hasRelatedWork W4306412145 @default.
• W4317862796 hasVolume "41" @default.
• W4317862796 isParatext "false" @default.
• W4317862796 isRetracted "false" @default.

• next